WO2000074721A1 - Vitamine pour therapie a double ciblage - Google Patents

Vitamine pour therapie a double ciblage Download PDF

Info

Publication number
WO2000074721A1
WO2000074721A1 PCT/AU2000/000618 AU0000618W WO0074721A1 WO 2000074721 A1 WO2000074721 A1 WO 2000074721A1 AU 0000618 W AU0000618 W AU 0000618W WO 0074721 A1 WO0074721 A1 WO 0074721A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
complex
folate
enzyme
cbl
Prior art date
Application number
PCT/AU2000/000618
Other languages
English (en)
Inventor
Gregory John Russell-Jones
John Fergus Mcewan
Original Assignee
Biotech Australia Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Limited filed Critical Biotech Australia Pty Limited
Priority to CA002376175A priority Critical patent/CA2376175A1/fr
Priority to JP2001501255A priority patent/JP2003506319A/ja
Priority to AU47352/00A priority patent/AU4735200A/en
Publication of WO2000074721A1 publication Critical patent/WO2000074721A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to vitamin-mediated targeting for the delivery of agents and active substances in the therapy of disease. More particularly the invention relates to combined targeting using vitamins essential for cancer growth in vitamin complexes used to deliver cytotoxic drugs to tumors and cancer cells. The invention also relates to processes for preparing the complexes, pharmaceutical compositions containing same, methods of treatment involving the complexes and uses of the complexes in the manufacture of medicaments.
  • Chemotherapy has been, for many decades, one of the major approaches to the control and cure of malignant neoplasms (cancers).
  • cancer chemotherapy it is often necessary to increase the quantity of cytotoxic drugs administered in an exponential fashion in order to obtain a linear increase in the death of cancer cells. This in turn leads to an undesirable increase in non-specific cytotoxicity of bystander, healthy cells.
  • cytotoxin it is often necessary to repeatedly deliver smaller doses of cytotoxin, which inevitably leads to the survival of a small fraction of drug-resistant cells.
  • This in turn has necessitated the development of more specific and stronger cytotoxic drugs, however their nonselective action on cells other than cancerous cells still remains a major problem.
  • cytotoxic agent delivery In an attempt to increase the dose of cytotoxic agent delivered to the tumor cell, specific targeting agents such as monoclonal antibodies to "tumor-specific antigens" have been employed. While this therapy has proven to produce more specific targeting, in many instances it has not been possible to deliver enough cytotoxic agent coupled to the antibody for effective tumoricidal activity. Recently focus has switched to the use of molecules essential for growth to be used as targeting agents. In particular, research has concentrated on the use of vitamins and in particular folic acid and vitamin B, 2 (cobalamin, Cbl, VB 12 ) for tumour specific targeting.
  • Folate receptors are significantly over-expressed on a large proportion of human cancer cells including ovarian, breast, lung, endometrial, renal, colon, and cancers of myeloid hematopoietic cells.
  • FR- ⁇ folate receptors
  • FR- ⁇ folate receptors
  • FR- ⁇ is upregulated in malignant tissues of epithelial origin such as ovarian carcinoma
  • FR- ⁇ is overexpressed in malignant tissues of non-epithelial origin.
  • Folate-mediated tumor targeting has been exploited to date for delivery of the following molecules and molecular complexes (i) protein toxins, (ii) low-molecular-weight chemotherapeutic agents, (iii) radio-imaging agents (iv) MRI contrast agents, (v) radiotherapeutic agents, (vi) liposomes with entrapped drugs, (vii) genes, (viii) antisense oligonucleotides, (ix) ribozymes, and (x) immunotherapeutic agents.
  • TCII plasma protein transcolbamin II
  • RME receptor-mediated endocytosis
  • the other pathway involves the rearrangement of methyl malonyl CoA to succinyl CoA, and is catalyzed by methyl malonyl CoA mutase. It has recently been shown that the in vitro proliferation of human and murine leukemia cells is dependent upon both TCII and Cbl (see McLean, G. R., Quadros, E. B., Rothenberg, S. P., Morgan, A. C, Schrader, J. W., and Ziltener, H. J., Antibodies to transcobalamin II block in vitro proliferation of leukemic cells, Blood, 1997, 89, 235-242).
  • amplification of drug delivery can occur by linkage of a drug/ pharmaceutical to a bio-compatible polymer backbone to which a number of vitamin molecules are linked, either subsequently, previously or concurrently.
  • linkage to the polymer, or the polymer to which the pharmaceutical is linked should be biodegradable.
  • a pharmaceutical composition comprising a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are complexed to the same agent or active substance.
  • a pharmaceutical composition comprising a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are each complexed to different agents or active substances.
  • a method for the manufacture of a pharmaceutical composition of the present invention which method comprises admixing a first vitamin complex, one or more further vitamin complexes and a pharmaceutically acceptable carrier, excipient, diluent and/or adjuvant.
  • a pharmaceutical composition prepared by a method of the third aspect.
  • a method for the treatment, prophylaxis or amelioration of disease preferably cancer, which comprises administering to a subject a therapeutically effective amount of a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are complexed to the same agent or active substance.
  • a method for the treatment, prophylaxis or amelioration of disease preferably cancer, which comprises administering to a subject a therapeutically effective amount of a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are each complexed to different agents or active substances.
  • a seventh aspect of the present invention there is provided use of a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are complexed to the same agent or active substance in the preparation of a medicament for the treatment, prophylaxis or amelioration of disease, preferably cancer.
  • a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are each complexed to different agents or active substances in the manufacture of a medicament for the treatment, prophylaxis or amelioration of disease, preferably cancer.
  • kits for the delivery of one or more agents or active substances to a subject comprising a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are complexed to the same agent or active substance.
  • kits for the delivery of agents or active substances to a subject comprising a first vitamin complex and a second vitamin complex wherein the vitamin of the first complex is different to the vitamin of the second complex and wherein both vitamins are each complexed to different agents or active substances.
  • compositions of the present invention may further comprise a pharmaceutically acceptable carrier, excipient, diluent and/or adjuvant and optionally one or more further vitamin complexes either the same as or different from either of the first or second vitamin complexes of the composition.
  • Figure 1 represents the targeting of a tumor with a pharmaceutical composition of the present invention comprising a Cbl-targeting complex and a folate-targeting complex.
  • Figure 1 a subject is depicted in which the star (1) represents a tumor, the crescent (2) represents the liver and the ovals (3) represent the kidneys.
  • Figure 1 A shows the targeting of a tumor with a Cbl complex and the unwanted accumulation of the Cbl complex in the liver.
  • Figure 1 B shows the targeting of a tumor with a folate complex and the unwanted accumulation of the folate complex in the kidneys.
  • Figure IC shows the dual targeting of a tumor with a folate complex/Cbl complex composition of the present invention.
  • An advantage provided by the present invention is the ability to amplify agent or active substance delivery to a subject by the use of different vitamin complexes.
  • the vitamin complexes preferentially target tumor tissues and cancer cells for it is in these tissues and cells that there often is an upregulation of vitamin receptors.
  • Vitamins suitable for making vitamin complexes include, amongst others, folic acid, VB, 2 , riboflavin and biotin, more preferably folic acid and VB I2 . It will be understood that derivatives and analogues of vitamins are also within the scope of the present invention.
  • Analogues contemplated herein include, but are not limited to, modification to the ring structure, functional groups or side chains of the vitamin molecule including the additional removal of protecting groups and salts and complexes thereof derived from any source such as being chemically synthesized or identified by screening process such as natural product screening provided that the analogue possesses some binding activity for the vitamin receptor. It will be understood by those skilled in the art that upregulated receptors other than just the vitamin receptors on tumor or cancer cells can be targeted by the complexes of the present invention.
  • compositions of the present invention is either by the simultaneous or sequential administration of vitamin complexes, preferably a folate complex and a VB 12 complex.
  • the vitamin complexes deliver agents or active substances, in particular hormones, drugs, prodrugs, enzymes, proteins, peptides, toxins, immunogens or DNA or RNA analogues to subjects.
  • Suitable toxins for use in the invention include, but are not limited to, ricin, abrin, diphtheria toxin, modecin, tetanus toxin, mycotoxins, mellitin, ⁇ -amanitin, pokeweed antiviral protein, ribosome inhibiting proteins, especially those of wheat, barley, corn, rye, gelonin and maytansinoid.
  • Suitable cytotoxic agents for use in the invention include, but are not limited to, alkylating agents such as chlorambucil, cyclophosphamide, melphalan, cyclopropane; anthracycline antitumor antibiotics such as doxorubicin, daunomycin, adriamycin, mitomycin C, 2-(hydroxymethyl)anthraquinone; antimetabolites such as methotrexate, dichloromethatrexate: cisplatin, carboplatin, and metallopeptides containing platinum, copper, vanadium, iron, cobalt, gold, cadmium, zinc and nickel.
  • alkylating agents such as chlorambucil, cyclophosphamide, melphalan, cyclopropane
  • anthracycline antitumor antibiotics such as doxorubicin, daunomycin, adriamycin, mitomycin C, 2-(hydroxymethyl)anthra
  • agents include DON, thymidine, pentamethylmelamin, dianhydrogalactitol, 5-Methyl-THF, anguidine, maytansine, neocarzinostatin. chlorozotocin, AZQ, 2'deoxycoformycin, PALA, AD-32, m-AMSA and rnisonidazole.
  • different vitamins are conjugated to the same type of active substance.
  • Administration of the vitamin complexes so produced results in the complexes targeting cancer cells which are upregulated for those vitamins whilst at the same time unwanted accumulation of the vitamin complexes is spread over different organs and tissues which also happen to be targeted by the particular vitamins.
  • different vitamins are conjugated to different active substances. This also results in the amplification of, for example, cytotoxic agents to target cells in combination drug therapy.
  • first vitamin conjugate with a relatively non-toxic prodrug of a cytotoxic agent together with or sequentially to a second vitamin conjugate with a relatively non-toxic enzyme.
  • the first vitamin conjugate may for example use folic acid as the targeting vitamin.
  • the folate moiety targets the tumor tissue to be treated and also happens to target the kidneys, delivering the prodrug rather than the cytotoxic agent itself.
  • Sequential or simultaneous administration of the second vitamin conjugate using for example a VB 12 -enzyme complex will target the tumor and the liver, as a result of the VB 12 targeting.
  • the enzyme is adapted to transform the prodrug into a cytotoxic agent which directly acts on the targeted tumor tissue.
  • the toxicities of the administered vitamin complexes are greatly reduced because substantially less cytotoxic drug will be synthesized in other tissues and organs in the treated subject. This is a result of some accumulation in the kidneys of relatively non-toxic folate-prodrug complex but little or no delivery of the VB ]2 -enzyme complex, whilst there is some accumulation of the relatively non-toxic VB I2 -enzyme in the liver but little or no delivery of the folate-prodrug complex.
  • the subject firstly receives a dose of an antibody-enzyme conjugate, after which the patient then receives a dose of a prodrug conjugate.
  • a cytotoxic agent is then synthesised or released from the prodrug conjugate at the targeted tumor site by the action of the enzyme.
  • the agents or active substances may be delivered by existing encapsulation methods or polymer-drug complexes.
  • Polymers suitable for the formation of nanoparticles by solvent evaporation include, amongst others, poly-lactic acid, poly-(Lactide/co-glycolide), poly- hydroxybutyrate, poly-hydroxyvalerate, poly-(hydroxybutyrate/valerate), ethyl cellulose, dextran. polysaccharides, polyalkylcyanoacrylate, poly-methyl-methacrylate, poly(e- caprolactone) and various combinations and co-polymers of the above.
  • Polymers suitable for the formation of microspheres by interfacial precipitation/polymerization include, amongst others, EUDRAGITTM ; Poly(N a ,N e -L- lysinediylterephthaloyl); polymers formed by the reaction of Lysine hydrochloride and p- phthaloyl dichloride; by the reaction of acryloylated maltodextrin or acryloylated hydroxyethyl starch with ammonium peroxodisulfate and N,N,N',N'- tetramethylethylenediamine.
  • Microspheres can also be formed by the polymerization of various diamines such as ethylene diamine, phenylenediamine, toluene diamine, hexamethylene diamine, or diols such as ethylene diol, bisphenol, resorcinol, catechol, pentanediol, hexanediol, dodecanediol, 1 ,4-butanediol, with diacid chlorides such as sebacoylchloride and adipoyl chloride, or diisocynates such as hexamethylene diisocyanate using the methods fully described in EP 85870002.4.
  • diamines such as ethylene diamine, phenylenediamine, toluene diamine, hexamethylene diamine, or diols such as ethylene diol, bisphenol, resorcinol, catechol, pentanediol, hexanediol,
  • Polymers suitable for the formation of microspheres by polymer phase separation include co-poly(vinyl chloride: vinyl alcohol: vinyl acetate), cellulosic polymers, poly vinyl acetate, polyvinyl alcohol, polyvinylchloride, natural and synthetic rubbers, polyacrylates, polystyrene and the like. Methods to synthesize such microspheres are fully described in USP 4,166,800.
  • Polymers suitable for the formation of microspheres by complex coacervation include, amongst others, mixtures of polyanions, such as gum arabic, alginate, carboxymethyl cellulose, carboxymethyl starch, polystyrene sulfonic acid, polyvinyl sulfonic acid, poly- d-glucuronic acid, poly-pyruvic acid, carrageenan, heparin sulphate, polyphosphate with polycations, such as polylysine, gelatin.
  • polyanions such as gum arabic, alginate, carboxymethyl cellulose, carboxymethyl starch, polystyrene sulfonic acid, polyvinyl sulfonic acid, poly- d-glucuronic acid, poly-pyruvic acid, carrageenan, heparin sulphate, polyphosphate with polycations, such as polylysine, gelatin.
  • Polymers suitable for the formation of microspheres by Polymer/Polymer incompatibility include, amongst others, ethyl cellulose, ethylene vinyl acetate polymer, poly(lactide), or poly(vinylidene chloride) mixed with polymers such as polyethylene, silicone, polyisobutylene or polybutadiene.
  • microspheres include, starch, cross-linked albumen, polyacrylamide, cross-linked gelatin and others known to those skilled in the art of microsphere preparation.
  • Suitable polymer-drug complexes utilise targeting molecules to deliver agents or active substances as described in the above mentioned folate-polymer complex patent application (PCT/AU00/00406, filed 4 May 2000) and the VB 12 -polymer complex patent (Russell-Jones et al, 1995 USP 5,449,720) and are described below as follows:-
  • Polymers useful according to the invention include potentially biodegradable polymers such as dextran and its derivatives, amino acid polymers such poly-lysine, poly-glutamic acid.
  • Non-biodegradable polymers include poly[N-(2-hydroxypropyl)-methacrylamide], to which is attached biodegradable side chains such as those containing ester linkages, or amino acid sequences cleavable within lysosomal vacuoles i.e. Gly-Phe-Leu-Gly (see Rihova, B. and Kopecek J., Biological properties of targetable poly[N-(2-hydroxypropyl)- methacrylamide]-antibody complexes, J. Control Rel, 1985, 2:289-310).
  • vitamin targeting agents may be linked to polymers to which are linked various enzymes, drugs, and cytotoxic agents for the control of tumour growth.
  • targeting agent-polymer-drug conjugates are suitable for parenteral delivery to tumors as they can utilise the aforementioned targeting agent (TA) receptor system for uptake binding and uptake, and have the added advantage of increasing the amount of pharmaceutical agent which can be delivered via the TA uptake mechanism.
  • TA targeting agent
  • a further advantage of using polymers in combination with folic acid, or an analogue thereof, as a TA, is their ability to avoid or at least reduce targeting to the kidneys by virtue of their size.
  • the linkage joining the pharmaceutical, or the TA to the polymer is a disulfide bond. In a further embodiment of the invention the linkage joining the pharmaceutical, or the TA to the polymer is an ester linkage. In yet another embodiment of the invention the linkage joining the pharmaceutical or the TA to the polymer is a ⁇ -glutamyl- ⁇ -lysine bond. In yet another embodiment of the invention the linkage joining the pharmaceutical or the TA to the polymer is a diazo-linkage.
  • vitamin polymer complexes have the general formula: (TA-Q) n -P-(Q'-A) m wherein, TA, is either vitamin B 12 or an analogue thereof which will bind via TCII to surface receptors on tumor cells, or where TA is folate or an analogue thereof which will bind via folate receptors to surface receptors on tumor cells, and where n, the molar substitution ration of TA in the complex, is in the range from 1.0 to 50.0, and
  • P is a pharmaceutically acceptable polymer
  • A is a pharmaceutically active substance
  • m the molar substitution ratio of A in the complex
  • Q and Q' are independently a covalent bond, or a spacer compound linking folate, P and A by covalent bonds.
  • the polymer, P, of the present invention can be any pharmaceutically acceptable polymer.
  • the polymer is able to attach to at least one carrier molecule and to at least one, but preferably a multiplicity of active substance molecules.
  • Suitable polymers for substitution with folate and modification according to the invention include poly[N-(2-hydroxypropyl)-methacrylamide], dextran, chondroitan sulfate, water soluble polyurethanes formed by covalent linkage of PEG with lysine, poly(glutamic acid), poly(hydroxypropyl glutamine) and branched chain polypeptides formed by the dual modification of the ⁇ - and ⁇ -amino groups of lysine during the peptide synthesis.
  • Such polymers may have multiple amino-termini, to which can be conjugated a plurality of the pharmaceutical or drug to be delivered.
  • the polymers can also be formed with multiple cystines, to provide free thiols, or multiple glutamates or aspartates, to provide free carboxyls for conjugation using suitable carbodiimides.
  • the polymer can contain multiple histidines or tyrosines for conjugation.
  • Folate is most easily covalently attached to a ligand, or the polymer, via either its ⁇ or ⁇ carboxylic acid moiety. It has been shown, however, that the -carboxyl derivatives have low avidity for the folate receptor, whereas the ⁇ -carboxy derivatives have similar affinity to native folate.
  • the spacer compounds Q and Q' are optional. When they are absent the carrier (folate or a suitable derivative of vitamin B 12 ) and/or the active substance A are linked to polymer P by a direct covalent bond. They are introduced either to improve the receptor affinity of the carrier complex or to overcome problems in the coupling of the carrier, and/or the active substance A arising from unfavourable steric interactions between the carrier and A with the polymer P, or to increase the bioactivity of A in the complex.
  • the spacer compounds may also act as linking agents, being bi-functional compounds with selected functional groups on each end to react with suitable functional groups located on the polymer, and also on the vitamin carrier molecule and/or on the pharmaceutically active substances. Polymers to which are conjugated various cytotoxic drugs have been previously described.
  • vitamin conjugate pairs can be used provided that different vitamins target and deliver, either directly or indirectly, agents or active substances to the same site to be treated.
  • Preferred vitamin complex pairs include, amongst others, the following:
  • Particularly preferred enzyme prodrug combinations suitable for the invention include the following peptidase substrate pairs:-
  • the vitamin complexes used in the present invention may also be formed from more than one active substance linked to a polymer, which is linked to at least one targeting agent (vitamin).
  • the ability of the targeting agent to undergo the binding reactions necessary for uptake and transport of the active substance in a vertebrate host and the activity of the active substance are substantially maintained, following conjugation or following biological release of the active substance from the polymer.
  • Suitable methods for the manufacture of these vitamin complexes comprises one or more of the following steps: a) reacting the active substance with the polymer to form said complex; b) chemically modifying the active substance to provide at least one functional group capable of forming a chemical linkage, and reacting the active substance and polymer to form said complex; c) chemically modifying the targeting agent to provide at least one functional group capable of forming a chemical linkage and reacting the targeting agent and polymer to form said complex; d) chemically modifying the active substance and the polymer to provide functional groups capable of forming a chemical linkage, and reacting the active substance and polymer to form said complex; e) reacting the active substance with at least one cross-linking agent and reacting the active substance of polymer to form said complex; f) reacting the targeting agent with at least one cross-linking agent and reacting the polymer and carrier to form said complex; g) reacting the active substance and polymer with at least one cross-linking agent and reacting the active substance and polymer to form said
  • the above method may also include modification of the polymeric support to introduce functional groups capable of reacting either directly with the active substance or with a chemically-modified form of the active substance.
  • the resulting polymer-active substance intermediate contains one or more molecules of the active substance, said intermediate being suitable for coupling to the targeting agent to give a complex capable of amplified delivery of the active substances.
  • Suitable extended spacers for the conjugation of the pharmaceutical, vitamin B l2 or folate to the polymer matrix include : disuccinimidyl suberate (DSS), b/-?(sulfosuccinimidyl) suberate (BSS), ethylene glycolb/ ' -.(succinimidylsuccinate) (EGS), ethylene glycolb/_.(sulfosuccinimidylsuccinate) (Sulfo-EGS), p-amino-phenylacetic acid, dithiob.-.
  • DSP succinimidylpropionate
  • DTSSP disuccinimidyl tartarate
  • Sulfo-DST disuccinimidyl tartarate
  • BSOCOES bw[2-(succinimidyloxycarbonyloxy)-ethylene]sulfone
  • Sulfo-BSOCOES dimethyl adipimidate.2 HC1 (DMA), dimethyl pimelimidate.2 HC1 (DMP), dimethyl suberimidate.2 HC1 (DMS), N-succinimidyl(4-iodoacetyl)aminobenzoate (SIAB) andsuccinimidyl 4-(p-maleimidophyl)butyrate (SMPB).
  • Suitable cross-linking agents for use in the preparation of thiol-cleavable biodegradable linkers include ⁇ -succinimidyl 3-(2-pyridyldithio)propionate (SPDP), iminothiolane, sulfosuccinimidyl 6-[3-(2-pyridyldithio) propionamido] hexanoate (Sulfo-LC-SPDP), succinimidyl 6-[3-(2-pyridyldithio) propionamido] hexanoate (LC-SPDP), sulfosuccinimidyl 6-[ ⁇ -methyl- ⁇ -(2-pyridyldithio) toluamido]hexanoate (Sulfo-LC- SMPT), l,4-di[3'-(2'-pyridyldithio)propionamido]butane (DPDPB), 4- succini
  • Suitable analogues of VB 12 for derivatization prior to conjugation to the polymer include any variant or derivative of VB, 2 (cyanocobalamin) which possesses binding activity to intrinsic factor.
  • Preferred analogues of VB, 2 also include aquocobalamin, adenosylcobalamin, methylcobalamin, hydroxycobalamin, cyanocobalamin, carbanalide, and 5-methoxybenzylcyanocobalamin [(5-MeO)CN-Cbl] as well as the desdimethyl, monoethylamide and the methylamide analogues of all of the above.
  • analogues include all alkyl cobalamins in which the alkyl chain is linked to the corrin nucleus by a direct CoC covalent bond.
  • Other analogues include chlorocobalamin, sulfitocobalamin, nitrocobalamin, thiocyanatocobalamin, benzimidazolecyanocobalamin derivatives such as 5,6-dichlorobenzimidazole, 5-hydroxybenzimidazole, trimethylbenzimidazole, as well as adenosylcyanocobalamin [(Ade)CN-Cbl], cobalamin lactone, cobalamin lactam and the anilide, ethylamide, monocarboxylic and dicarboxylic acid derivatives of VB :2 or its analogues.
  • Preferred derivatives of VB I2 also include the mono-, di- and tricarboxylic acid derivatives or the propionamide derivatives of VB )2 .
  • Targeting molecules may also include analogues of VB 12 in which the cobalt is replaced by zinc or nickel.
  • the corrin ring of VB ]2 or its analogues may also be substituted with any substituent which does not effect its binding to IF, and such derivatives of VB 12 or its analogues are part of this invention.
  • Other derivatives of VB ]2 or its analogues which have a functional group which is able to react with the spacer compound are also part of the invention.
  • Other derivatives and analogues of VB 12 are discussed in Schneider, Z. and Stroinski, A., Comprehensive VB]2 (Walter De Gruyter; Berlin, NY; 1987), the disclosure of which is incorporated herein by reference.
  • Still other derivatives of VB ]2 include those in which the 5'-hydroxyl group of the ribose moiety of the nucleotide ligand is modified. These derivatives include, but are not limited to derivatives formed by reaction with succinic anhydride, glutaric anhydride, p- maleimidophenyl isocyanate, oxirane, benzoquinone or cyanuric chloride. Alternatively derivatives can be formed by activation with l '-carbonyldiimidazole and subsequent reaction with diamino-spacers, amino-acid-spacers, or alternatively with amino-alkyl chains to form hydrophobic derivatives (see Vitamin B ]2 derivatives and methods for their production. PCT/AU99/00462, filed 11 June 1999, Russell- Jones, G. J., and McEwen, J. F.).
  • folate as used herein is to be considered in its broadest context and refers to the carboxylic acid anion of folic acid and, where not stated, the counter cation may be any suitable cation inlcuding pharmaceutically acceptable cations and may also include a proton, i.e. folic acid.
  • the term "folate” may be taken to include reference to analogues of the folate molecule, such as methotrexate, and preferably where the analogue possesses some binding activity for the folic acid receptor.
  • treatment and prophylaxis are to be considered in its broadest context.
  • treatment does not necessarily imply that a host is treated until total recovery.
  • prophylaxis does not necessarily mean that the subject will not eventually contract a disease condition.
  • treatment and prophylaxis include amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition.
  • prophylaxis may be considered as reducing the severity of onset of a particular condition. “Treatment” may also reduce the severity of an existing condition.
  • the subject of the treatment or prophylaxis is a vertebrate host, preferably a veterinary , domestic or agricultural animal or human, or more preferably a mammal such as but not limited to human, primate, livestock animal (eg. sheep, cow, horse, donkey, pig) companion animal (eg. dog, cat) laboratory test animal (eg. mouse, rabbit, rat, guinea pig, hamster) captive wild animal (eg. fox, deer).
  • livestock animal eg. sheep, cow, horse, donkey, pig
  • companion animal eg. dog, cat
  • laboratory test animal eg. mouse, rabbit, rat, guinea pig, hamster
  • captive wild animal eg. fox, deer
  • the agents herein defined may be coadministered with one or more other compounds or molecules.
  • the pharmaceutical compositions of the invention may be administered in combination with other chemotherapeutic agents or other ameliorative acitve substances.
  • administered in combination is meant simultaneous administaration in the same formulation or in two different formulatinos via the same or different routs or sequential administration by the same or different routes.
  • sequential administratino is meant a time difference of from seconds, minutes, hours or days between the administration of the formulations.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of super factants.
  • the preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimersal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying abso ⁇ tion, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilisation.
  • dispersions are prepared by incorporating the various sterilised active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • the active ingredients When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, gels, pastes, viscous colloidal dispersions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 1% by weight of active compound.
  • compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 ⁇ g and 2000 mg of active compound.
  • the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
  • the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; buffering agents such as sodium bicarbonate to neutralise or buffer stomach acid; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • buffering agents such as sodium bicarbonate to neutralise or buffer
  • any material may be present as coatings or to otherwise modify the physical form of the dosage unit.
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and formulations.
  • Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired.
  • Administration of the agent in the form of a pharmaceutical composition may be performed by any convenient means.
  • the agent of the pharmaceutical composition is contemplated to exhibit therapeutic activity when administered in an amount which depends on the particular case. Variation depends for example, on the human or animal and the agent chosen. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, weekly, monthly or other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the situation.
  • the agent may be administered in any suitable manner.
  • Routes of administration include, but are not limited to, respiratorally, intratracheally, nasopharyngeally, intravenously, intraperitoneally, subcutaneously, intracranially, intradermally, intramuscularly, intraoccularly, intrathecally, intracereberally, intranasally, infusion, orally, rectally. via IV drip, patch and implant.
  • suitable routes are via injection into vessels which supply the tumour or diseased organs.
  • Peptides may also be installed into cavities for example the pleural or peritoneal cavity or injected directly into tumour tissues.
  • MLP2 multi-Lysine polymer of the general formula [(NH 2 -Gly)j 6 -Lysg-Lys4-His 4 - Glu 4 -Lys 2 -Lys]-Gly5-Cys-COOH was synthesized on an Applied Biosystems peptide synthesiser. More precisely the structure can be represented as follows:
  • Folic acid (5g) was dissolved in 100 ml dry DMSO, plus 2.5 ml triethylamine. N- hydroxysuccinimide (2.6 gm) was added as a powder to the folic acid and reacted overnight with 4.7 gm dicyclohexylcarbodiimide at room temperature. The dicyclohexylurea was removed by filtration. The DMSO was concentrated under reduced pressure and heating, and ⁇ HS-folate precipitated with diethylether. The product, was washed several times with anhydrous ether, dried under vacuum and stored as a yellow powder.
  • toxins which could be used for formation of folate-MLP -toxin conjugates, including momordin, psuedomonas exotoxin A, ricin and abrin.
  • a general method for the formation of folate-MLP-toxin conjugates is described below.
  • Conjugates are prepared in which the covalent linker contains a biodegradable disulfide bond, which would be reduced in vivo, presumably by intracellular glutathione in the tumor cell, thereby releasing the active substance after transport from the serum into the tumor cell. Briefly, MLP1 or MLP2 was reacted with N-succinimidyl 3-(2- pyridyldithio)propionate (SPDP).
  • SPDP N-succinimidyl 3-(2- pyridyldithio)propionate
  • the dithiopyridyl-MLP (DTP-MLP) product was purified by RP-HPLC.
  • a free thiol was introduced onto the toxin by a two step procedure in which the toxin was firstly reacted with SPDP, after which the thiopyridyl group was with mercapto-ethanol.
  • the product was purified by RP-HPLC.
  • free thiol was introduced into the toxin directly by reaction with iminothiolane.
  • the thiolated product (SH-HN + toxin) was purified by RP-HPLC.
  • Folate was linked to the polymer-toxin complexes by reacting adipyl-hydraxidylfolate derivative with the complex using ED AC. The reacted product was purified by RP- HPLC.
  • a chlorambucil-tetra peptide prodrug was synthesized that contained a sequence cleavable by intracellular lysosomal enzymes.
  • the tetra peptide, Gly-Phe-Leu-Gly was synthesized by standard Merrifield synthesis. Chlorambucil (61 mg) and carbonyl diimidazole (32 mg) were dissolved in dry DMF (300 ⁇ l) and the solution stirred at room temperature for 1 hour. A solution of Gly-Phe-Leu-Gly (75 mg, in 300 ⁇ l DMF) was added dropwise to the active ester, followed by diisopropylethylamide (DIEA) (150 ⁇ l), and the solution was allowed to react overnight.
  • DIEA diisopropylethylamide
  • a chlorambucil-tetra peptide prodrug was synthesized that contained a sequence that is not cleavable by intracellular lysosomal enzymes.
  • the dipeptide, Gly-Gly was purchased from Sigma. Chlorambucil (61 mg) and carbonyl diimidazole (32 mg) were dissolved in dry DMF (300 ⁇ l) and the solution stirred at room temperature for 1 hour. A solution of Gly-Gly (75 mg, in 300 ⁇ l DMF) was added dropwise to the active ester, followed by diisopropylethylamide (DIEA) (150 ⁇ l), and the solution was allowed to react overnight.
  • DIEA diisopropylethylamide
  • the unreacted chlorambucil was extracted in the DCM phase of a water/DCM wash, and the Chlorambucil-Gly- Gly product was isolated from the aqueous phase by chromatography on RP-HPLC using a linear gradient of 5-100% acetonitrile.
  • Carboxypeptidase A (Boeringher) (10 mg) was precipitated from solution by centrifugation. The resultant precipitate was resuspended in distilled water and dialysed extensively overnight against DW.
  • the "e"monocarboxylic acid isomer of vitamin B 12 was dissolved at 100 mg/ml in DMF (5 mg in 50 ⁇ l).
  • DIEA 1.5 ⁇ l
  • TSTU O-(N- succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
  • the activated ester was then added to the carboxypeptidase A in 2% NaHCO 3 and allowed to react overnight. Unreacted vitamin B ]2 was removed by extensive dialysis against distilled water.
  • the present invention provides a simple and novel technique for the specific dual targeting of diseased tissue and cells and the amplification of drug/pharmaceutical delivery to the tissues and cells.
  • the present invention also provides novel compositions for use in targeting those tissues and cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne le ciblage par vitamine dont le but est d'administrer des agents et des substances actives dans le cadre de la thérapie de maladie. Un ciblage combiné à base de vitamines indispensable à la croissance de cancer est utilisé sous forme de complexes de l'invention de façon à amplifier l'apport de médicaments cytotoxiques vers les tumeurs et les cellules cancéreuses, tout en réduisant dans le même temps la toxicité à l'encontre du patient traité.
PCT/AU2000/000618 1999-06-02 2000-05-31 Vitamine pour therapie a double ciblage WO2000074721A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002376175A CA2376175A1 (fr) 1999-06-02 2000-05-31 Vitamine pour therapie a double ciblage
JP2001501255A JP2003506319A (ja) 1999-06-02 2000-05-31 ビタミンに関連したデュアルターゲッティング治療法
AU47352/00A AU4735200A (en) 1999-06-02 2000-05-31 Vitamin directed dual targeting therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ0712 1999-06-02
AUPQ0712A AUPQ071299A0 (en) 1999-06-02 1999-06-02 Vitamin directed dual targeting therapy

Publications (1)

Publication Number Publication Date
WO2000074721A1 true WO2000074721A1 (fr) 2000-12-14

Family

ID=3814910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2000/000618 WO2000074721A1 (fr) 1999-06-02 2000-05-31 Vitamine pour therapie a double ciblage

Country Status (4)

Country Link
JP (1) JP2003506319A (fr)
AU (2) AUPQ071299A0 (fr)
CA (1) CA2376175A1 (fr)
WO (1) WO2000074721A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028592A1 (fr) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Conjugues de cobalamine utiles comme agents d'imagerie et agents antitumoraux
WO2003097647A1 (fr) * 2002-05-15 2003-11-27 Endocyte, Inc. Conjugues vitamine-mitomycine
WO2004045647A1 (fr) * 2002-11-21 2004-06-03 Access Pharmaceuticals Australia Pty Ltd Amplification du ciblage medie par la biotine
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US6838073B1 (en) 1999-10-15 2005-01-04 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
EP1592457A2 (fr) * 2003-01-27 2005-11-09 Endocyte, Inc. Conjugues de delivrance de medicaments de liaison au recepteur de vitamines
US8105608B2 (en) 2000-03-31 2012-01-31 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
US9090563B2 (en) 2004-07-23 2015-07-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
CN111789957A (zh) * 2020-07-23 2020-10-20 苏州大学 敲低lncBCAS1-4_1细胞株与活性维生素D联用在制备抗肿瘤药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
JP5289935B2 (ja) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
ES2468240T3 (es) 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
WO2008101231A2 (fr) 2007-02-16 2008-08-21 Endocyte, Inc. Procédés et compositions de traitement et de diagnostic d'une maladie rénale

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774089A (en) * 1985-06-14 1988-09-27 Albion International, Inc. Stimulation of gonadotropic hormones with mineral mixtures containing amino acid chelates
WO1994027613A1 (fr) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Systemes de diffusion orale a mediation par la vitamine b12 destines au gcsf et a l'epo
WO1994027641A1 (fr) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Amplification du systeme d'adsorption de la vitamine b12 par des polymeres
WO1995027723A1 (fr) * 1994-04-08 1995-10-19 Receptagen Corporation Agents modulateurs de recepteurs et procede associes
WO1997014740A1 (fr) * 1995-10-19 1997-04-24 Receptagen Corporation Polyethylene glycols de longueur discrete
WO1999065930A1 (fr) * 1998-06-12 1999-12-23 Biotech Australia Pty. Limited Derives de vitamine b12 et leurs methodes de preparation
WO1999065529A1 (fr) * 1998-06-15 1999-12-23 Alza Corporation Complexes de cobalamine et d'acide nucleique et leur utilisation en therapie genique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774089A (en) * 1985-06-14 1988-09-27 Albion International, Inc. Stimulation of gonadotropic hormones with mineral mixtures containing amino acid chelates
WO1994027613A1 (fr) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Systemes de diffusion orale a mediation par la vitamine b12 destines au gcsf et a l'epo
WO1994027641A1 (fr) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Amplification du systeme d'adsorption de la vitamine b12 par des polymeres
WO1995027723A1 (fr) * 1994-04-08 1995-10-19 Receptagen Corporation Agents modulateurs de recepteurs et procede associes
WO1997014740A1 (fr) * 1995-10-19 1997-04-24 Receptagen Corporation Polyethylene glycols de longueur discrete
WO1999065930A1 (fr) * 1998-06-12 1999-12-23 Biotech Australia Pty. Limited Derives de vitamine b12 et leurs methodes de preparation
WO1999065529A1 (fr) * 1998-06-15 1999-12-23 Alza Corporation Complexes de cobalamine et d'acide nucleique et leur utilisation en therapie genique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GINOBBI P. ET AL.: "Folic acid - polylysine carrier improves efficacy of C-myc antisense oligodeoxynucleotides on human melanoma (M/4) cells", ANTICANCER RESEARCH, vol. 17, 1997, pages 29 - 36 *
LEAMON CHRISTOPHER P. ET AL.: "Folate-copolymer-mediated transfection of cultured cells", BIOCONJUGATE CHEM., vol. 10, 1999, pages 947 - 957 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US6838073B1 (en) 1999-10-15 2005-01-04 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
WO2001028592A1 (fr) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Conjugues de cobalamine utiles comme agents d'imagerie et agents antitumoraux
US7179445B2 (en) 1999-10-15 2007-02-20 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US8105608B2 (en) 2000-03-31 2012-01-31 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
JP4814520B2 (ja) * 2002-05-15 2011-11-16 エンドサイト，インコーポレイテッド ビタミン−マイトマイシン結合体
WO2003097647A1 (fr) * 2002-05-15 2003-11-27 Endocyte, Inc. Conjugues vitamine-mitomycine
JP2005531564A (ja) * 2002-05-15 2005-10-20 エンドサイト，インコーポレイテッド ビタミン−マイトマイシン結合体
EP2060272A3 (fr) * 2002-05-15 2009-05-27 Endocyte, Inc. Conjugués vitamine-mitomycine
WO2004045647A1 (fr) * 2002-11-21 2004-06-03 Access Pharmaceuticals Australia Pty Ltd Amplification du ciblage medie par la biotine
EP1592457A4 (fr) * 2003-01-27 2010-09-08 Endocyte Inc Conjugues de delivrance de medicaments de liaison au recepteur de vitamines
JP2011256184A (ja) * 2003-01-27 2011-12-22 Endocyte Inc ビタミン受容体結合性薬剤送達結合体
EP1592457A2 (fr) * 2003-01-27 2005-11-09 Endocyte, Inc. Conjugues de delivrance de medicaments de liaison au recepteur de vitamines
EP2529758A3 (fr) * 2003-01-27 2013-01-02 Endocyte, Inc. Conjugués d'administration de médicaments à liaison au récepteur de vitamines
EP2517729A3 (fr) * 2003-01-27 2013-01-02 Endocyte, Inc. Conjugués d'administration de médicaments à liaison au récepteur de vitamines
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
US10647676B2 (en) 2004-07-23 2020-05-12 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9090563B2 (en) 2004-07-23 2015-07-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US10738086B2 (en) 2007-06-25 2020-08-11 Endocyte Inc. Conjugates containing hydrophilic spacer linkers
US10500204B2 (en) 2007-06-25 2019-12-10 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9745341B2 (en) 2007-10-25 2017-08-29 Endocyte, Inc. Tubulysins and processes for preparing
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US11344623B2 (en) 2012-02-24 2022-05-31 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US10765756B2 (en) 2012-02-24 2020-09-08 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9884124B2 (en) 2012-05-17 2018-02-06 Extend Biosciences, Inc. Carriers for improved drug delivery
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10420819B2 (en) 2014-10-22 2019-09-24 Extend Biosciences, Inc. Insulin vitamin D conjugates
US10702574B2 (en) 2014-10-22 2020-07-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10406202B2 (en) 2014-10-22 2019-09-10 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
US11510910B2 (en) 2016-02-23 2022-11-29 Tva (Abc), Llc HSP90 targeted conjugates and particles and formulations thereof
CN111789957A (zh) * 2020-07-23 2020-10-20 苏州大学 敲低lncBCAS1-4_1细胞株与活性维生素D联用在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
AUPQ071299A0 (en) 1999-06-24
CA2376175A1 (fr) 2000-12-14
AU4735200A (en) 2000-12-28
JP2003506319A (ja) 2003-02-18

Similar Documents

Publication Publication Date Title
WO2000074721A1 (fr) Vitamine pour therapie a double ciblage
AU4094300A (en) Amplification of folate-mediated targeting to tumor cells using polymers
US20060127310A1 (en) Amplification of biotin-mediated targeting
Kopeček et al. HPMA copolymers: origins, early developments, present, and future
Etrych et al. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties
AU706723B2 (en) Amplification of the VB-12 uptake system using polymers
Ulbrich et al. Structural and chemical aspects of HPMA copolymers as drug carriers
Yang et al. Macromolecular therapeutics
US7807134B2 (en) Multidrug multiligand conjugates for targeted drug delivery
US8603990B2 (en) Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation
CZ20032430A3 (cs) Konjugáty z hydroxyalkylškrobu a účinné látky
JPH08510262A (ja) Ｇｃｓｆ及びｅｐｏ用ビタミンｂ▲下１▼▲下２▼介在経口デリバリーシステム
CA2257245A1 (fr) Complexes medicamenteux
WO2007080114A2 (fr) Conjugué de macromolecule
WO2000025825A1 (fr) Composes dds et procede de dosage de ces composes
Mohan et al. Polysaccharide peptide conjugates: chemistry, properties and applications
US20050220754A1 (en) Vitamin directed targeting therapy
US20030103934A1 (en) Drugs having long-term retention in target tissue
KR100795093B1 (ko) 여러가지 종류의 몸안에서 유효한 물질을 전달하는데 적합한 폴리양이온에 기초한 바이오콘쥬게이트를 제조하는 방법
Piorecka et al. Synthetic routes to nanoconjugates of anthracyclines
Chytil et al. Structural design and synthesis of polymer prodrugs
JP2003504312A (ja) 生物学的に活性な材料
Hudecz et al. Drug targeting by macromolecules without recognition unit?
Cuchelkar et al. Polymer–drug conjugates
AU2004201277A1 (en) Amplification of folate-mediated targeting to tumor cells using polymers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2001 501255

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2376175

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase